AIDS (London, England) 2017 01 24() doi 10.1097/QAD.0000000000001422
Liver-related morbidity and mortality is expanding in people living with HIV (PLHIV). Hepatocellular carcinoma (HCC), the third most lethal malignancy on a global scale, is a dominant complication of chronic liver disease and cirrhosis in patients with coexisting hepatitis. HIV infection further complicates the clinical heterogeneity of HCC posing concurrent challenges stemming from the underlying immunological status of the patients and the ongoing need for combined anti-retroviral therapy (cART). In this paper we review the multiple clinical implications that characterize the multidisciplinary management of HCC in the context of HIV infection.